Your account is not claimed yet. You can sign up with ORCID to claim your account.

Xu-Fei Huang (X Huang)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2019
Publications (10 Years): 4

Top Topics

Vascular Endothelial Growth Factor

Chronic Lymphocytic Leukemia

Coronary Artery

Top Venues

Blood cancer journal

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Hao Zhao, Xu-Fei Huang, Xue-Min Gao, Hao Cai, Lu Zhang, Jun Feng, Xin-Xin Cao, Dao-Bin Zhou, Jian Li
What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia 33 (4) (2019)
Jian Li, Xu-Fei Huang, Qian-Qian Cai, Chen Wang, Hao Cai, Hao Zhao, Lu Zhang, Xin-Xin Cao, Robert Peter Gale, Dao-Bin Zhou
A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. American journal of hematology 93 (6) (2018)
Hao Zhao, Hao Cai, Chen Wang, Xu-Fei Huang, Xin-Xin Cao, Lu Zhang, Dao-Bin Zhou, Jian Li
Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. Blood cancer journal 8 (4) (2018)
Xu-Fei Huang, C Zhang, C Wang, Q Cai, X Cao, H Cai, L Zhang, J Feng, D Zhou, J Li
Measurement of β-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilities. Blood cancer journal 6 (11) (2016)